stockportfolio.pro
Stocks / AMPH vs LMRI
AMPH vs LMRI
Amphastar Pharmaceuticals, Inc. and Lumexa Imaging Holdings, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Amphastar Pharmaceuticals, Inc. (AMPH) | Lumexa Imaging Holdings, Inc. (LMRI) | |
|---|---|---|
| Market cap | $0.9B | $0.9B |
| Revenue (latest FY) | $719.89M | $1.02B |
| Net income (latest FY) | $98.09M | $-47.10M |
| Revenue growth (5y CAGR) | 15.5% | 4.6% |
| Net margin | 13.6% | -4.6% |
| Return on equity | 12.4% | -8.0% |
| P/E ratio | 12.2 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 9 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AMPH — free Open LMRI — freeFrequently asked questions
Which is bigger, AMPH or LMRI?
Lumexa Imaging Holdings, Inc. is larger by market capitalization — $0.9B versus $0.9B.
Which grows faster, AMPH or LMRI?
Over the last five fiscal years, Amphastar Pharmaceuticals, Inc. grew revenue faster — 15.5%/yr versus 4.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.